亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

南京肽業(yè)生物科技有限公司多肽  

多肽,氨基酸

搜索
新聞中心
  • 暫無(wú)新聞
產(chǎn)品分類
  • 暫無(wú)分類
聯(lián)系方式
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無(wú)鏈接
首頁(yè) > 供應(yīng)產(chǎn)品 > 124584-08-3|奈西利肽
124584-08-3|奈西利肽
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 江蘇付款后3天內(nèi)
品牌 南京肽業(yè)
過(guò)期 長(zhǎng)期有效
更新 2020-11-05 13:59
 
詳細(xì)信息

中文名稱:奈西利肽

中文同義詞:奈西利肽;奈西立肽,>98%;ANP受體NRP1激動(dòng)劑(NESIRITIDE)

英文名稱:BNP-32(HUMAN)

英文同義詞:Nesiritide,BrainNatriureticPeptide-32human,BNP-32,>98%;BNP-32(human)hydrochloride;Nesiritide[USAN:INN];SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH(DISULFIDEBRIDGE:10-26);SER-PRO-LYS-MET-VAL-GLN-GLY-SER-GLY-CYS-PHE-GLY-ARG-LYS-MET-ASP-ARG-ILE-SER-SER-SER-SER-GLY-LEU-GLY-CYS-LYS-VAL-LEU-ARG-ARG-HIS;H-SChemicalbookER-PRO-LYS-MET-VAL-GLN-GLY-SER-GLY-CYS-PHE-GLY-ARG-LYS-MET-ASP-ARG-ILE-SER-SER-SER-SER-GLY-LEU-GLY-CYS-LYS-VAL-LEU-ARG-ARG-HIS-OH;H-SER-PRO-LYS-MET-VAL-GLN-GLY-SER-GLY-CYS-PHE-GLY-ARG-LYS-MET-ASP-ARG-ILE-SER-SER-SER-SER-GLY-LEU-GLY-CYS-LYS-VAL-LEU-ARG-ARG-HIS-OH(DISULFIDEBRIDGE:10-26);BRAINNATRIURETICPEPTIDE(1-32),HUMAN

CAS號(hào):124584-08-3

分子式:C143H244N50O42S4

分子量:3464.04

©2025 南京肽業(yè)生物科技有限公司多肽 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問(wèn)量:5140  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |